documents:
- abstract: ''
  authors: null
  chembl_release:
    chembl_release: CHEMBL_7
    creation_date: '2010-09-29'
  contact: null
  doc_type: DATASET
  document_chembl_id: CHEMBL1158643
  doi: null
  doi_chembl: null
  first_page: null
  issue: null
  journal: null
  journal_full_title: null
  last_page: null
  patent_id: null
  pubmed_id: null
  src_id: 0
  title: Unpublished dataset
  volume: null
  year: null
- abstract: ''
  authors: Clader JW.
  chembl_release:
    chembl_release: CHEMBL_1
    creation_date: '2009-09-03'
  contact: null
  doc_type: PUBLICATION
  document_chembl_id: CHEMBL1139451
  doi: 10.1021/jm030283g
  doi_chembl: null
  first_page: '1'
  issue: '1'
  journal: J Med Chem
  journal_full_title: Journal of medicinal chemistry.
  last_page: '9'
  patent_id: null
  pubmed_id: 14695813
  src_id: 1
  title: 'The discovery of ezetimibe: a view from outside the receptor.'
  volume: '47'
  year: 2004
- abstract: Okadaic acid (OA) is a toxin responsible for diarrhetic shellfish poisoning
    and is an extremely useful tool for studying processes that are regulated by phosphorylation,
    although the exact mechanism of action is still undetermined. We report on a study
    that proved the existence of OA in an unusual dimeric form when complexed with
    potassium ion. The proposed structure of this dimer is based on spectroscopic
    and conformational studies.
  authors: "Daranas AH, Fern\xE1ndez JJ, Morales EQ, Norte M, Gav\xEDn JA."
  chembl_release:
    chembl_release: CHEMBL_1
    creation_date: '2009-09-03'
  contact: null
  doc_type: PUBLICATION
  document_chembl_id: CHEMBL1148466
  doi: 10.1021/jm034189b
  doi_chembl: null
  first_page: '10'
  issue: '1'
  journal: J Med Chem
  journal_full_title: Journal of medicinal chemistry.
  last_page: '13'
  patent_id: null
  pubmed_id: 14695814
  src_id: 1
  title: Self-association of okadaic acid upon complexation with potassium ion.
  volume: '47'
  year: 2004
- abstract: A variety of novel heterocyclic compounds having thienoazepine, pyrroloazepine,
    furoazepine, and thienodiazepine skeletons were synthesized, most of which exhibited
    potent antagonism of [(3)H]-AVP specific binding in assays using rat liver (V1),
    rat kidney (V2), human platelet plasma membranes, and recombinant human CHO cells
    (V2), as well as antagonizing AVP-induced hypertension in rats (V1, intravenous)
    and showing a diuretic effect in rats (V2, oral). By detailed studies of the structure-activity
    relationships of these compounds, the thienoazepine derivative 1 was found to
    be a very potent combined V1 and V2 antagonist. After further pharmacological
    and toxicological evaluation as well as physical properties, the hydrochloride
    2 (JTV-605) of compound 1 was selected for clinical studies as a potent AVP antagonist
    with a long duration of action.
  authors: Cho H, Murakami K, Nakanishi H, Fujisawa A, Isoshima H, Niwa M, Hayakawa
    K, Hase Y, Uchida I, Watanabe H, Wakitani K, Aisaka K.
  chembl_release:
    chembl_release: CHEMBL_1
    creation_date: '2009-09-03'
  contact: null
  doc_type: PUBLICATION
  document_chembl_id: CHEMBL1139452
  doi: 10.1021/jm030287l
  doi_chembl: null
  first_page: '101'
  issue: '1'
  journal: J Med Chem
  journal_full_title: Journal of medicinal chemistry.
  last_page: '109'
  patent_id: null
  pubmed_id: 14695824
  src_id: 1
  title: 'Synthesis and structure-activity relationships of 5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepine
    derivatives: novel arginine vasopressin antagonists.'
  volume: '47'
  year: 2004
- abstract: The hemoglobin-degrading aspartic proteases plasmepsin I (Plm I) and plasmepsin
    II (Plm II) of the malaria parasite Plasmodium falciparum have lately emerged
    as putative drug targets. A series of C(2)-symmetric compounds encompassing the
    1,2-dihydroxyethylene scaffold and a variety of elongated P1/P1' side chains were
    synthesized via microwave-assisted palladium-catalyzed coupling reactions. Binding
    affinity calculations with the linear interaction energy method and molecular
    dynamics simulations reproduced the experimental binding data obtained in a Plm
    II assay with very good accuracy. Bioactive conformations of the elongated P1/P1'
    chains were predicted and agreed essentially with a recent X-ray structure. The
    compounds exhibited picomolar to nanomolar inhibition constants for the plasmepsins
    and no measurable affinity to the human enzyme cathepsin D. Some of the compounds
    also demonstrated significant inhibition of parasite growth in cell culture. To
    the best of our knowledge, these plasmepsin inhibitors represent the most selective
    reported to date and constitute promising lead compounds for further optimization.
  authors: "Ersmark K, Feierberg I, Bjelic S, Hamelink E, Hackett F, Blackman MJ,\
    \ Hult\xE9n J, Samuelsson B, Aqvist J, Hallberg A."
  chembl_release:
    chembl_release: CHEMBL_1
    creation_date: '2009-09-03'
  contact: null
  doc_type: PUBLICATION
  document_chembl_id: CHEMBL1139453
  doi: 10.1021/jm030933g
  doi_chembl: null
  first_page: '110'
  issue: '1'
  journal: J Med Chem
  journal_full_title: Journal of medicinal chemistry.
  last_page: '122'
  patent_id: null
  pubmed_id: 14695825
  src_id: 1
  title: Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II
    devoid of cathepsin D inhibitory activity.
  volume: '47'
  year: 2004
- abstract: A comparative NMR conformational analysis of three distinct tetrapeptide
    inhibitors of the Hepatitis C NS3 protease that differ at the 4-aryloxy-substituted
    P2 proline position was undertaken. Specifically, transferred nuclear Overhauser
    effect experiments in combination with restrained systematic conformational searches
    were used to characterize the orientation of the P2 aryl substituents of these
    inhibitors when bound to the NS3 protease. Differences between free and bound
    conformations were also investigated. Analysis of the results allowed the design
    of a new P2 aromatic substituent, which significantly increased the potency of
    our inhibitors. The bound conformation of a specific competitive inhibitor having
    this novel P2 substituent is also described, along with a model of this inhibitor
    bound to the NS3 protease. This NS3 protease/inhibitor complex model also supports
    a hypothetical stabilization role for the P2 residue of the substrates and/or
    inhibitors and further elucidates the subtle details of the binding of the P2
    residue of substrate-based inhibitors.
  authors: Goudreau N, Cameron DR, Bonneau P, Gorys V, Plouffe C, Poirier M, Lamarre
    D, Llinas-Brunet M.
  chembl_release:
    chembl_release: CHEMBL_1
    creation_date: '2009-09-03'
  contact: null
  doc_type: PUBLICATION
  document_chembl_id: CHEMBL1139454
  doi: 10.1021/jm0303002
  doi_chembl: null
  first_page: '123'
  issue: '1'
  journal: J Med Chem
  journal_full_title: Journal of medicinal chemistry.
  last_page: '132'
  patent_id: null
  pubmed_id: 14695826
  src_id: 1
  title: 'NMR structural characterization of peptide inhibitors bound to the Hepatitis
    C virus NS3 protease: design of a new P2 substituent.'
  volume: '47'
  year: 2004
- abstract: Human monoclonal antibodies (mAbs) designed for immunotherapy have a high
    potential for avoiding the complications that may result from human immune system
    responses to the introduction of nonhuman mAbs into patients. This study presents
    a characterization of cocaine/antibody interactions that determine the binding
    properties of the novel human sequence mAb 2E2 using three-dimensional quantitative
    structure-activity relationship (3D-QSAR) methodology. We have experimentally
    determined the binding affinities of mAb 2E2 for cocaine and 38 cocaine analogues.
    The K(d) of mAb 2E2 for cocaine was 4 nM, indicating a high affinity. Also, mAb
    2E2 displayed good cocaine specificity, as reflected in its 10-, 1500-, and 25000-fold
    lower binding affinities for the three physiologically relevant cocaine metabolites
    benzoylecgonine, ecgonine methyl ester, and ecgonine, respectively. 3D-QSAR models
    of cocaine binding were developed by comparative molecular similarity index analysis
    (CoMSIA). A model of high statistical quality was generated showing that cocaine
    binds to mAb 2E2 in a sterically restricted binding site that leaves the methyl
    group attached to the ring nitrogen of cocaine solvent-exposed. The methyl ester
    group of cocaine appears to engage in attractive van der Waals interactions with
    mAb 2E2, whereas the phenyl group contributes to the binding primarily via hydrophobic
    interactions. The model further indicated that an increase in partial positive
    charge near the nitrogen proton and methyl ester carbonyl group enhances binding
    affinity and that the ester oxygen likely forms an intermolecular hydrogen bond
    with mAb 2E2. Overall, the cocaine binding properties of mAb 2E2 support its clinical
    potential for development as a treatment of cocaine overdose and addiction.
  authors: Paula S, Tabet MR, Farr CD, Norman AB, Ball WJ.
  chembl_release:
    chembl_release: CHEMBL_1
    creation_date: '2009-09-03'
  contact: null
  doc_type: PUBLICATION
  document_chembl_id: CHEMBL1139455
  doi: 10.1021/jm030351z
  doi_chembl: null
  first_page: '133'
  issue: '1'
  journal: J Med Chem
  journal_full_title: Journal of medicinal chemistry.
  last_page: '142'
  patent_id: null
  pubmed_id: 14695827
  src_id: 1
  title: Three-dimensional quantitative structure-activity relationship modeling of
    cocaine binding by a novel human monoclonal antibody.
  volume: '47'
  year: 2004
- abstract: alpha,gamma-Diketo acids (DKA) were discovered from screening as selective
    and reversible inhibitors of hepatitis C virus NS5b RNA-dependent RNA polymerase.
    The diketo acid moiety proved essential for activity, while substitution on the
    gamma position was necessary for selectivity and potency. Optimization led to
    the identification of a DKA inhibitor of NS5b polymerase with IC(50) = 45 nM,
    one of the most potent HCV NS5b polymerase inhibitors reported.
  authors: Summa V, Petrocchi A, Pace P, Matassa VG, De Francesco R, Altamura S, Tomei
    L, Koch U, Neuner P.
  chembl_release:
    chembl_release: CHEMBL_1
    creation_date: '2009-09-03'
  contact: null
  doc_type: PUBLICATION
  document_chembl_id: CHEMBL1139456
  doi: 10.1021/jm0342109
  doi_chembl: null
  first_page: '14'
  issue: '1'
  journal: J Med Chem
  journal_full_title: Journal of medicinal chemistry.
  last_page: '17'
  patent_id: null
  pubmed_id: 14695815
  src_id: 1
  title: Discovery of alpha,gamma-diketo acids as potent selective and reversible
    inhibitors of hepatitis C virus NS5b RNA-dependent RNA polymerase.
  volume: '47'
  year: 2004
- abstract: Recently we reported the pharmacological characterization of the 9,10-dihydropyrrolo[1,3]benzothiazepine
    derivative (S)-(+)-8 as a novel atypical antipsychotic agent. This compound had
    an optimum pK(i) 5-HT(2A)/D(2) ratio of 1.21 (pK(i) 5-HT(2A) = 8.83; pK(i) D(2)
    = 7.79). The lower D(2) receptor affinity of (S)-(+)-8 compared to its enantiomer
    was explained by the difficulty in reaching the conformation required to optimally
    fulfill the D(2) pharmacophore. With the aim of finding novel atypical antipsychotics
    we further investigated the core structure of (S)-(+)-8, synthesizing analogues
    with specific substituents; the structure-activity relationship (SAR) study was
    also expanded with the design and synthesis of other analogues characterized by
    a pyrrolo[2,1-b][1,3]benzothiazepine skeleton, substituted on the benzo-fused
    ring or on the pyrrole system. On the 9,10-dihydro analogues the substituents
    introduced on the pyrrole ring were detrimental to affinity for dopamine and for
    5-HT(2A) receptors, but the introduction of a double bond at C-9/10 on the structure
    of (S)-(+)-8 led to a potent D(2)/5-HT(2A) receptor ligand with a typical binding
    profile (9f, pK(i) 5-HT(2A)/D(2) ratio of 1.01, log Y = 8.43). Then, to reduce
    D(2) receptor affinity and restore atypicality on unsaturated analogues, we exploited
    the effect of specific substitutions on the tricyclic system of 9f. Through a
    molecular modeling approach we generated a novel series of potential atypical
    antipsychotic agents, with optimized 5HT(2A)/D(2) receptor affinity ratios and
    that were easier to synthesize and purify than the reference compound (S)-(+)-8.
    A number of SAR trends were identified, and among the analogues synthesized and
    tested in binding assays, 9d and 9m were identified as the most interesting, giving
    atypical log Y scores respectively 4.98 and 3.18 (pK(i) 5-HT(2A)/D(2) ratios of
    1.20 and 1.30, respectively). They had a multireceptor affinity profile and could
    be promising atypical agents. Compound 9d, whose synthesis is easier and whose
    binding profile is atypical (log Y score similar to that of olanzapine, 3.89),
    was selected for further biological investigation. Pharmacological and biochemical
    studies confirmed an atypical antipsychotic profile in vivo. The compound was
    active on conditioned avoidance response at 1.1 mg/kg, a dose 100-times lower
    than that required to cause catalepsy (ED(50) >90 mg/kg), it induced a negligible
    increase of prolactin serum levels after single and multiple doses, and antagonized
    the cognitive impairment induced by phencyclidine. In conclusion, the pharmacological
    profile of 9d proved better than clozapine and olanzapine, making this compound
    a potential clinical candidate.
  authors: Campiani G, Butini S, Fattorusso C, Catalanotti B, Gemma S, Nacci V, Morelli
    E, Cagnotto A, Mereghetti I, Mennini T, Carli M, Minetti P, Di Cesare MA, Mastroianni
    D, Scafetta N, Galletti B, Stasi MA, Castorina M, Pacifici L, Vertechy M, Di Serio
    S, Ghirardi O, Tinti O, Carminati P.
  chembl_release:
    chembl_release: CHEMBL_1
    creation_date: '2009-09-03'
  contact: null
  doc_type: PUBLICATION
  document_chembl_id: CHEMBL1139457
  doi: 10.1021/jm0309811
  doi_chembl: null
  first_page: '143'
  issue: '1'
  journal: J Med Chem
  journal_full_title: Journal of medicinal chemistry.
  last_page: '157'
  patent_id: null
  pubmed_id: 14695828
  src_id: 1
  title: Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists.
    Molecular modeling, further structure-activity relationship studies, and identification
    of novel atypical antipsychotic agents.
  volume: '47'
  year: 2004
- abstract: The Boehringer Ingelheim compound collection was screened for inhibitors
    of the ATPase activity of human papillomavirus E1 helicase to develop antiviral
    agents that inhibit human papillomavirus (HPV) DNA replication. This screen led
    to the discovery of (biphenyl-4-sulfonyl)acetic acid 1, which inhibits the ATPase
    activity of HPV type 6 E1 helicase with a low micromolar IC(50) value. A hit-to-lead
    exercise rapidly converted 1 into a low nanomolar lead series.
  authors: "Faucher AM, White PW, Brochu C, Grand-Ma\xEEtre C, Rancourt J, Fazal G."
  chembl_release:
    chembl_release: CHEMBL_1
    creation_date: '2009-09-03'
  contact: null
  doc_type: PUBLICATION
  document_chembl_id: CHEMBL1139458
  doi: 10.1021/jm034206x
  doi_chembl: null
  first_page: '18'
  issue: '1'
  journal: J Med Chem
  journal_full_title: Journal of medicinal chemistry.
  last_page: '21'
  patent_id: null
  pubmed_id: 14695816
  src_id: 1
  title: Discovery of small-molecule inhibitors of the ATPase activity of human papillomavirus
    E1 helicase.
  volume: '47'
  year: 2004
- abstract: A series of benzoxazinones has been synthesized and tested for PPARgamma
    agonist activity. Synthetic approaches were developed to provide either racemic
    or chiral compounds. In vitro functional potency could be measured through induction
    of the aP2 gene, a target of PPARgamma. These studies revealed that compounds
    with large aliphatic chains at the nitrogen of the benzoxazinone were the most
    potent. Substitution of the chain was tolerated and in many cases enhanced the
    in vitro potency of the compound. Select compounds were further tested for metabolic
    stability, oral bioavailability in rats, and efficacy in db/db mice after 11 days
    of dosing. In vivo analysis with 13 and 57 demonstrated that the series has potential
    for the treatment of type 2 diabetes.
  authors: Rybczynski PJ, Zeck RE, Dudash J, Combs DW, Burris TP, Yang M, Osborne
    MC, Chen X, Demarest KT.
  chembl_release:
    chembl_release: CHEMBL_1
    creation_date: '2009-09-03'
  contact: null
  doc_type: PUBLICATION
  document_chembl_id: CHEMBL1148467
  doi: 10.1021/jm0301888
  doi_chembl: null
  first_page: '196'
  issue: '1'
  journal: J Med Chem
  journal_full_title: Journal of medicinal chemistry.
  last_page: '209'
  patent_id: null
  pubmed_id: 14695833
  src_id: 1
  title: Benzoxazinones as PPARgamma agonists. 2. SAR of the amide substituent and
    in vivo results in a type 2 diabetes model.
  volume: '47'
  year: 2004
- abstract: Tumor tissues have an acidic microenvironment with a pH from 6.0 to 7.0,
    whereas the intra- and extracellular milieu of normal cells is 7.4. We have found
    that the hydrolysis of sodium trioxodinitrate (Angeli's salt; 1) to hydroxyl radical
    (*OH) was 10 times higher at pH = 6.0 than at pH = 7.4. It is hypothesized that
    the formation of *OH in solutions of 1 reflects the hydrolysis of the latter compound
    to nitroxyl (HNO) which dimerizes to cis-hyponitrous acid (HO-N=N-OH; 3) with
    concomitant azo-type homolytic fission to N(2) and *OH. In weakly acidified solutions,
    1 exhibited strong toxicity to cancer cells that was inhibited by scavengers of
    hydroxyl radical, whereas no toxicity was observed at pH = 7.4. In a subcutaneous
    xenograft model of pheochromocytoma, 1 markedly inhibited tumor growth at a dose
    that was nontoxic to nude mice. These data suggest that the H(+)-amplified production
    of *OH from 1, and maybe other precursors of HNO, could be a selective mechanism
    for destruction cells with an acidic intra- or extracellular microenvironment.
  authors: Stoyanovsky DA, Schor NF, Nylander KD, Salama G.
  chembl_release:
    chembl_release: CHEMBL_1
    creation_date: '2009-09-03'
  contact: null
  doc_type: PUBLICATION
  document_chembl_id: CHEMBL1139459
  doi: 10.1021/jm030192j
  doi_chembl: null
  first_page: '210'
  issue: '1'
  journal: J Med Chem
  journal_full_title: Journal of medicinal chemistry.
  last_page: '217'
  patent_id: null
  pubmed_id: 14695834
  src_id: 1
  title: Effects of pH on the cytotoxicity of sodium trioxodinitrate (Angeli's salt).
  volume: '47'
  year: 2004
- abstract: Chemical aspects of mode of action of imexon and related cyanoaziridines
    were studied. These compounds do not alkylate DNA nor react with the epsilon-amino
    groups of l-lysine, despite the presence of an aziridine ring. They do react readily
    with biologically important sulfhydryl compounds to give products derived from
    either aziridine ring opening, interaction with the cyano group of cyanoaziridines,
    or opening of the iminopyrrolidone ring of imexon. The products from reactions
    of imexon and related cyanoaziridines with thiols are not as potent as their parent
    compounds against tumor cells. These results are consistent with biological studies
    that show that the mechanism of cytotoxicity involves thiol depletion followed
    by oxidative stress leading to apoptosis.
  authors: Iyengar BS, Dorr RT, Remers WA.
  chembl_release:
    chembl_release: CHEMBL_1
    creation_date: '2009-09-03'
  contact: null
  doc_type: PUBLICATION
  document_chembl_id: CHEMBL1146638
  doi: 10.1021/jm030225v
  doi_chembl: null
  first_page: '218'
  issue: '1'
  journal: J Med Chem
  journal_full_title: Journal of medicinal chemistry.
  last_page: '223'
  patent_id: null
  pubmed_id: 14695835
  src_id: 1
  title: Chemical basis for the biological activity of imexon and related cyanoaziridines.
  volume: '47'
  year: 2004
- abstract: The paper describes the design, synthesis, and testing of inhibitors of
    folate-synthesizing enzymes and of whole cell cultures of Candida albicans. The
    target enzymes used were dihydropteroic acid synthase (SYN) and dihydrofolate
    reductase (DHFR). Several series of new 2,4-diaminopyrimidines were synthesized
    and tested as inhibitors of DHFR and compared with their activity against DHFR
    derived from mycobacteria and Escherichia coli. To test for selectivity, also
    rat DHFR was used. A series of substituted 4-aminodiphenyl sulfones was tested
    for inhibitory activity against SYN and the I(50) values compared to those obtained
    previously against Plasmodium berghei- and E. coli-derived SYN. Surprisingly,
    QSAR equations show very similar structural dependencies. To find an explanation
    for the large difference in the I(50) values observed for enzyme inhibition (SYN,
    DHFR) and for inhibition of cell cultures of Candida, mutant strains with overexpressed
    efflux pumps and strains in which such pumps are deleted were included in the
    study and the MICs compared. Efflux pumps were responsible for the low activity
    of some of the tested derivatives, others showed no increase in activity after
    pumps were knocked out. In this case it may be speculated that these derivatives
    are not able to enter the cells.
  authors: "Otzen T, Wempe EG, Kunz B, Bartels R, Lehwark-Yvetot G, H\xE4nsel W, Schaper\
    \ KJ, Seydel JK."
  chembl_release:
    chembl_release: CHEMBL_1
    creation_date: '2009-09-03'
  contact: null
  doc_type: PUBLICATION
  document_chembl_id: CHEMBL1139439
  doi: 10.1021/jm030931w
  doi_chembl: null
  first_page: '240'
  issue: '1'
  journal: J Med Chem
  journal_full_title: Journal of medicinal chemistry.
  last_page: '253'
  patent_id: null
  pubmed_id: 14695838
  src_id: 1
  title: Folate-synthesizing enzyme system as target for development of inhibitors
    and inhibitor combinations against Candida albicans-synthesis and biological activity
    of new 2,4-diaminopyrimidines and 4'-substituted 4-aminodiphenyl sulfones.
  volume: '47'
  year: 2004
- abstract: Thio analogues of purine, pyridine, and pyrimidine were prepared based
    on the initial activity screening of several analogues of these heterocycles against
    Mycobacterium tuberculosis (Mtb). Certain 6-thio-substituted purine analogues
    described herein showed moderate to good inhibitory activity. In particular, two
    purine analogues 9-(ethylcarboxymethyl)-6-(decylthio)-9H-purine (20) and 9-(ethylcarboxymethyl)-6-(dodecylthio)-9H-purine
    (21) exhibited MIC values of 1.56 and 0.78 microg/mL respectively against the
    Mtb H(37)Rv strain. N(9)-Substitution apparently enhances the antimycobacterial
    activity in the purine series described herein.
  authors: Pathak AK, Pathak V, Seitz LE, Suling WJ, Reynolds RC.
  chembl_release:
    chembl_release: CHEMBL_1
    creation_date: '2009-09-03'
  contact: null
  doc_type: PUBLICATION
  document_chembl_id: CHEMBL1149166
  doi: 10.1021/jm030389b
  doi_chembl: null
  first_page: '273'
  issue: '1'
  journal: J Med Chem
  journal_full_title: Journal of medicinal chemistry.
  last_page: '276'
  patent_id: null
  pubmed_id: 14695841
  src_id: 1
  title: Antimycobacterial agents. 1. Thio analogues of purine.
  volume: '47'
  year: 2004
- abstract: 'Both quantitative and qualitative chemical function based pharmacophore
    models of endothelin-A (ET(A)) selective receptor antagonists were generated by
    using the two algorithms HypoGen and HipHop, respectively, which are implemented
    in the Catalyst molecular modeling software. The input for HypoGen is a training
    set of 18 ET(A) antagonists exhibiting IC(50) values ranging between 0.19 nM and
    67 microM. The best output hypothesis consists of five features: two hydrophobic
    (HY), one ring aromatic (RA), one hydrogen bond acceptor (HBA), and one negative
    ionizable (NI) function. The highest scoring Hip Hop model consists of six features:
    three hydrophobic (HY), one ring aromatic (RA), one hydrogen bond acceptor (HBA),
    and one negative ionizable (NI). It is the result of an input of three highly
    active, selective, and structurally diverse ET(A) antagonists. The predictive
    power of the quantitative model could be approved by using a test set of 30 compounds,
    whose activity values spread over 6 orders of magnitude. The two pharmacophores
    were tested according to their ability to extract known endothelin antagonists
    from the 3D molecular structure database of Derwent''s World Drug Index. Thereby
    the main part of selective ET(A) antagonistic entries was detected by the two
    hypotheses. Furthermore, the pharmacophores were used to screen the Maybridge
    database. Six compounds were chosen from the output hit lists for in vitro testing
    of their ability to displace endothelin-1 from its receptor. Two of these are
    new potential lead compounds because they are structurally novel and exhibit satisfactory
    activity in the binding assay.'
  authors: Funk OF, Kettmann V, Drimal J, Langer T.
  chembl_release:
    chembl_release: CHEMBL_1
    creation_date: '2009-09-03'
  contact: null
  doc_type: PUBLICATION
  document_chembl_id: CHEMBL1139440
  doi: 10.1021/jm031041j
  doi_chembl: null
  first_page: '2750'
  issue: '11'
  journal: J Med Chem
  journal_full_title: Journal of medicinal chemistry.
  last_page: '2760'
  patent_id: null
  pubmed_id: 15139753
  src_id: 1
  title: Chemical function based pharmacophore generation of endothelin-A selective
    receptor antagonists.
  volume: '47'
  year: 2004
- abstract: A series of novel alpha-ketoamides incorporating stereoisomeric residues
    with different electronic properties at the P(1)'-position were synthesized to
    study the electronic requirements for inhibitor binding to the S(1)'-subsite of
    calpain I. The results of the study suggested the presence of an acidic amino
    acid residue at the S(1)'-subsite of calpain I. For example, ester 1a (Cbz-l-Leu-l-Phe-CO-d-Phe-OMe)
    was over 450-fold more potent than its carboxylic acid derivative 2a (Cbz-l-Leu-l-Phe-CO-d-Phe-OH).
    Additionally, amidino derivative 3a (Cbz-l-Leu-l-Phe-CONH-d-CH[C(NH)NH(2)]Bn)
    was about 6000-fold more potent than 2a. Furthermore, 4a (Cbz-l-Leu-l-Phe-CONHCH(2)Bn)
    was 12-fold less potent than its aza analogue 4b (Cbz-l-Leu-l-Phe-CONHNHBn). The
    results are consistent with the presence of an acidic amino acid residue at the
    S(1)'-subsite of calpain I. The acidic amino acid residue was found to be Glu261
    via molecular modeling studies.
  authors: Donkor IO, Han J, Zheng X.
  chembl_release:
    chembl_release: CHEMBL_1
    creation_date: '2009-09-03'
  contact: null
  doc_type: PUBLICATION
  document_chembl_id: CHEMBL1139441
  doi: 10.1021/jm0301336
  doi_chembl: null
  first_page: '72'
  issue: '1'
  journal: J Med Chem
  journal_full_title: Journal of medicinal chemistry.
  last_page: '79'
  patent_id: null
  pubmed_id: 14695821
  src_id: 1
  title: Design, synthesis, molecular modeling studies, and calpain inhibitory activity
    of novel alpha-ketoamides incorporating polar residues at the P1'-position.
  volume: '47'
  year: 2004
- abstract: Work in this laboratory has been involved with the design of aziridinyl
    quinone-based cancer drugs (PBIs) capable of both recognizing the DNA major groove
    and cleaving the phosphate backbone upon reduction to the hydroquinone. The hydroquinone
    species recognizes the major groove of DNA at single base pairs by Hoogsteen-type
    hydrogen bonding. The present study extends recognition beyond a single base pair
    by adding amino acid residues to the 3-amino center of the PBI system. Thus, extension
    with proline or proline-glycine results in phosphate cleavage at 5'-AA-3' with
    insignificant N(7) guanine alkylation. Molecular models were used to validate
    the observed sequence specificity. This report also describes the design of PBIs
    not capable of DNA alkylation. Removal of major groove interactions by methylation
    or the presence of steric bulk prevented DNA alkylation reactions upon reductive
    activation. From these studies it was concluded that DNA alkyation was not necessary
    for PBI cytostatic and cytotoxic activity. For example, linkage of two phenylalanines
    to the PBI results in highly selective cytostatic and cytotoxic activity against
    melanoma, although this compound is a weak DNA alkylator.
  authors: Ghodousi A, Huang X, Cheng Z, Skibo EB.
  chembl_release:
    chembl_release: CHEMBL_1
    creation_date: '2009-09-03'
  contact: null
  doc_type: PUBLICATION
  document_chembl_id: CHEMBL1139442
  doi: 10.1021/jm0302750
  doi_chembl: null
  first_page: '90'
  issue: '1'
  journal: J Med Chem
  journal_full_title: Journal of medicinal chemistry.
  last_page: '100'
  patent_id: null
  pubmed_id: 14695823
  src_id: 1
  title: Pyrrolobenzimidazoles linked to heterocycles and peptides. Design of DNA
    base pair specific phosphate hydrolyzing agents and novel cytotoxic agents.
  volume: '47'
  year: 2004
- abstract: Three C4'-acyl derivatives (5-7) of GL-331 (4) were synthesized and evaluated
    for cytotoxic and DNA topoisomerase II (topo II) inhibitory activity. All three
    compounds were cytotoxic against KB and KB-7d cells. Compounds 5 and 7, but not
    6, were potent inhibitors of the DNA topoisomerase II in vitro and this relative
    activity ranking was maintained for cytotoxicity, in vitro cell growth inhibition,
    and ability to induce cellular double-strand DNA breaks. These results provided
    new information on the structure-activity relationships of the C4' molecular area
    of 4-analogues.
  authors: Han S, Xiao Z, Bastow KF, Lee KH.
  chembl_release:
    chembl_release: CHEMBL_1
    creation_date: '2009-09-03'
  contact: null
  doc_type: PUBLICATION
  document_chembl_id: CHEMBL1139443
  doi: 10.1016/j.bmcl.2004.02.102
  doi_chembl: null
  first_page: '2979'
  issue: '11'
  journal: Bioorg Med Chem Lett
  journal_full_title: Bioorganic & medicinal chemistry letters.
  last_page: '2982'
  patent_id: null
  pubmed_id: 15125972
  src_id: 1
  title: 'Antitumor agents. Part 230: C4''-esters of GL-331 as cytotoxic agents and
    DNA topoisomerase II inhibitors.'
  volume: '14'
  year: 2004
- abstract: A number of substituted piperazinyl oxazolidinone derivatives have been
    synthesized and their antibacterial activities were evaluated by MIC determination.
    A systematic SAR was carried out to get highly potent oxazolidinone derivatives.
  authors: Lohray BB, Lohray VB, Srivastava BK, Gupta S, Solanki M, Kapadnis P, Takale
    V, Pandya P.
  chembl_release:
    chembl_release: CHEMBL_1
    creation_date: '2009-09-03'
  contact: null
  doc_type: PUBLICATION
  document_chembl_id: CHEMBL1139444
  doi: 10.1016/j.bmcl.2004.04.024
  doi_chembl: null
  first_page: '3139'
  issue: '12'
  journal: Bioorg Med Chem Lett
  journal_full_title: Bioorganic & medicinal chemistry letters.
  last_page: '3142'
  patent_id: null
  pubmed_id: 15149661
  src_id: 1
  title: 'Oxazolidinone: search for highly potent antibacterial.'
  volume: '14'
  year: 2004
page_meta:
  limit: 20
  next: /chembl/api/data/document.yaml?limit=20&offset=20
  offset: 0
  previous: null
  total_count: 99142
